
Sandoz to Pay $450 Million to Settle U.S. Generic Drug Probe, Reaffirms Guidance
The Swiss generic drugmaker will resolve long-running U.S. litigation over alleged anti-competitive practices without admitting wrongdoing and confirmed its financial outlook remains unchanged.







